about 
SpeedWeed
AUGUST 11, 2021
MAPS Makes History. This will be the second clinical trial to give cannabis medicine or placebos to participating military veterans, and according to the Chief Science Officer of the MAPS Public Benefit Corporation, Berra Yazar-Klosinki, PhD, the first trial was a great success. “We
Canna Law Blog
JANUARY 3, 2023
Now though, it sounds like FDA is serious about CBD regulations in the context of both food and supplements. A little CBD history. It’s really anyone’s guess about what lies ahead. It’s not like the FDA is unaware of the massive unregulated CBD market that already exists in the U.S. So, stay tuned!
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
FEBRUARY 28, 2022
Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Patents on psychedelics raise unique concerns associated with their unusual qualities, history, and regulation. Trial of Psilocybin Versus Escitalopram for Depression , 384 NEW ENG. Mitchell et al.,
SpeedWeed
MARCH 18, 2021
That’s about the amount of cannabis contained in two to three joints. They also wrote: The study sample included participants with a history of cannabis use. for the production of cannabis used in federally-regulated clinical trials. Wasn’t the DEA going to let others grow research-grade cannabis?
Veriheal
AUGUST 31, 2020
About Nishtha: Nishtha is pursuing neurology to become a physician-scientist in honor of her grandmother Nani who suffered from Alzheimer’s. About Sinibaldo: Sinibaldo is an aspiring healthcare professional and a biomedical researcher in the Medical Scientist Training Program (M.D./Ph.D.) Nishtha Tripathi. Sinibaldo Romero Arocha .
Cannabis Law Report
MARCH 2, 2020
This landmark approval is unique in that ketamine is well known to have hallucinogenic properties, as well as a long history as a party drug. Any approved medicines will have to be rescheduled by the Drug Enforcement Administration (DEA). Fortunately, this issue shouldn’t be a show-stopper. Potential IPOs within the next year.
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history.
Expert insights. Personalized for you.
52 
Let's personalize your content